S&P 500
5.018,39 -17,30 (-0,34%) Nasdaq
15.605,48 -52,34 (-0,33%) NIKKEI 225
38.260,75 -13,30 (-0,03%) Dólar/Euro
1,0720 +0,0002 (+0,02%) Petróleo Brent
83,95 +0,51 (+0,61%) Bitcoin EUR
53.655,39 -2.528,71 (-4,50%)
Axsome Therapeutics, Inc. (AXSM)
Después del cierre:
Axsome Therapeutics, Inc.
One World Trade Center
22nd Floor
New York, NY 10007
United States
212 332 3241
https://www.axsome.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 545
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Herriot Tabuteau M.D. | Founder, Chairman, CEO & President | 1,4M | N/A | 1968 |
| Mr. Hunter Murdock Esq. | General Counsel & Secretary | 757,31k | N/A | 1980 |
Descripción
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Gobierno corporativo
El ISS Governance QualityScore de Axsome Therapeutics, Inc., a día 29 de abril de 2024, es 8. Las puntuaciones base son Auditoría: 8; Tablero: 8; Derechos de los accionistas: 8; Compensación: 8.
